Crt-402
Preclinical
Crt-402 is one of 7 therapeutic programs targeting Autoimmune. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
6 competitors in Autoimmune
#DrugCompanyPhaseTrials
1Wayrilz
GGenzyme, a Sanofi Company
Phase 3
Fludara
SanofiPhase 1
Cytoxan
BBaxter Healthcare Corporation
Phase 1
Anti-CD19 CAR NK Cells
PPersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
CAR-NK Cells
HHangzhou Cheetah Cell Therapeutics Co., Ltd
Phase 1
4SCAR T Cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Crt-402
MMyeloid Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Crt-402. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- MMyeloid Therapeutics